glp-1 sglt2 Perspectives in weight control in diabetes – inhibitors and GLP-1–glucagon dual agonism Frontiers | Effects of SGLT2

Ninety-five percent of GLP-1 users report eating smaller portions, and 87% are snacking less, and 81% are eating less frequentlysignaling a significant shift in eating habits among users

Also, since SGLT-2 inhibitors are also known to have significant CV benefits, studies with more SGLT-2 inhibitor use in the comparator arm could have prevented the ability to detect a difference produced by the study GLP-1 RA

But there are still risks

If a formulation can consistently achieve 20% to 30% sublingual bioavailability, the gap between drops and injections narrows considerably

People want and need to hear that its not the easy way out